Ke Zhu

Partner

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Ke Zhu is a seasoned corporate transactional lawyer who specializes in Hong Kong IPOs, large-scale cross-border mergers and acquisitions, and private equity investments. He has represented a number of PRC and international companies in connection with Hong Kong public offerings and cross-border mergers and acquisitions.

Ke is well versed in highly complex and critical corporate transactions and works tenaciously to achieve successful results on behalf of his clients. He is responsive, highly skilled, and dedicated to the sustainability and success of his clients.

VIEW MORE

Languages

  • Mandarin Chinese

Admissions

Bar Admission

  • New York
  • Hong Kong

Education

  • Columbia University, LL.M.
  • University of Oxford Faculty of Law, LL.M.
  • Huazhong University Science & Technology, LL.B.

Professional Activities

Member

  • American Bar Association
  • Hong Kong Law Society

IPO Transactions

  • Honliv Healthcare Management Group Company Limited in its US$41.3 million IPO and listing on the Hong Kong Stock Exchange
  • Hygeia Healthcare Holdings Co., Limited in its US$286 million IPO and listing on the Hong Kong Stock Exchange
  • Yeahka Limited in its US$212 million IPO and listing on the Hong Kong Stock Exchange
  • Peijia Medical Limited in its US$343 million IPO and listing on the Hong Kong Stock Exchange
  • Akeso Biopharma in its US$383 million IPO and listing on the Hong Kong Stock Exchange
  • Guotai Junan Capital as sole sponsor and Guotai Junan Securities (Hong Kong) as main underwriter, and other underwriters in the US$65 million IPO and listing of Zhongguancun Science-Tech Leasing on the Hong Kong Stock Exchange
  • First Shanghai Capital as sole sponsor and First Shanghai Securities as sole global coordinator, and other underwriters in the US$71 Million IPO and listing of Chen Lin Education Group on the Hong Kong Stock Exchange
  • Shanghai Kindly Medical Instrument Co., Ltd., in its US$106 million IPO and listing on the Hong Kong Stock Exchange
  • Pharmaron in its approximately US$588 million dual primary listing and H share offering in Hong Kong
  • Aesthetic Medical International Holdings in its US$34.5 million IPO on the Nasdaq
  • China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$40 million IPO of mobile game publisher Digital Hollywood Interactive Limited (2022.HK) on the Hong Kong Stock Exchange
  • Viva Biotech (1873.HK) in its HK$1,521.5 million (approximately US$194 million) IPO and listing on the Hong Kong Stock Exchange
  • Bank of Qingdao (03866.HK) in its US$531 million IPO and listing on the Hong Kong Stock Exchange
  • Holly Futures Co., Ltd., a leading China-based futures company, in its US$63 million IPO of H-shares on the Main Board of the Hong Kong Stock Exchange
  • UBS as sole global coordinators, bookrunner, lead manager and sponsor in the US$106 million IPO of China Huirong Financial Holdings Ltd. on the Main Board of the Hong Kong Stock Exchange
  • Morgan Stanley and CCBI as joint sponsors and joint global coordinators in the US$250 million IPO of Harmonicare Medical Holdings Limited on the Main Board of the Hong Kong Stock Exchange
  • Chanjet Information Technology Company Limited in the US$116 million IPO of its H-shares on the Main Board of the Hong Kong Stock Exchange. This was the first spin-off listing of an A-share listed company on the Hong Kong Stock Exchange
  • China Vanke Co., Ltd. in the conversion of US$2.1 billion B-shares into H-shares and the listing of the H-shares on the Main Board of the Hong Kong Stock Exchange by way of introduction
  • Guosen Securities (HK) Capital Company Limited as sole sponsor in the conversion of Livzon Pharmaceutical Group Inc.’s US$548 million B-shares into H-shares and listing of the H-shares on the Main Board of the Hong Kong Stock Exchange by way of introduction
  • China International Marine Containers (Group) Co., Ltd. in the conversion of US$1.8 billion B-shares into H-shares and listing of the H-shares on the Main Board of the Hong Kong Stock Exchange by way of introduction. This was the first B-to-H listing on the Hong Kong Stock Exchange
  • CITIC Securities, UBS, and Bank of America Merrill Lynch as joint global coordinators and other underwriters in the US$319 million IPO of the H-shares of Huadian Fuxin Energy Corporation on the Main Board of the Hong Kong Stock Exchange
  • Haitong Securities Co. Ltd. in the US$1.68 billion IPO of its H-shares on the Main Board of the Hong Kong Stock Exchange
  • Morgan Stanley, Citigroup, and Credit Suisse as joint global coordinators and other syndicate of banks in the US$12 billion global offering and dual listing of Glencore International in both London and Hong Kong
  • CICC and Morgan Stanley as joint sponsors in the listing of Guangzhou Auto by way of introduction through privatization of a HK-listed auto company on the Main Board of the Hong Kong Stock Exchange
  • Microport Scientific Corporation in its US$200 million IPO on the Main Board of the Hong Kong Stock Exchange 
VIEW MORE

Press Releases

O’Melveny Advises Honliv Healthcare in its Hong Kong IPO

July 13, 2020

O’Melveny Advises Hygeia in its US$286 Million Hong Kong IPO

June 29, 2020

O’Melveny Advises Yeahka in US$212 million Hong Kong IPO

June 1, 2020

O’Melveny Advises Peijia Medical in its US$300+ Million Hong Kong IPO

May 15, 2020

O’Melveny Advises Akeso Biopharma in its Landmark US$333 Million Hong Kong IPO

April 24, 2020

O'Melveny Represents Sponsor and Underwriters in Hong Kong IPO of Zhongguancun Science-Tech Leasing

January 21, 2020

O’Melveny Represents Sponsor and Underwriters in US$71 Million Hong Kong IPO of Chen Lin Education Group

December 13, 2019

O'Melveny Represents Pharmaron in its US$588 million Hong Kong IPO

November 28, 2019

O'Melveny Represents Essence International in Highpower's Going-Private Transaction

November 11, 2019

O’Melveny Represents Shanghai Kindly Medical Instruments in US$106 Million Hong Kong IPO

November 8, 2019

O'Melveny Represents Aesthetic Medical International Holdings in its Nasdaq IPO

October 26, 2019

O’Melveny Represents Viva Biotech in its US$194 Million Hong Kong IPO

May 9, 2019

In the News

Alerts and Publications